Benin vs Kazakhstan: Average cost of drugs for extensively drug-resistant tuberculosis
Benin
6,274 constant 2022 US$
in 2024
Kazakhstan
6,329 constant 2022 US$
in 2023
Benin rank
6th
Kazakhstan rank
5th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Benin
- Kazakhstan
How they compare
Kazakhstan currently reports 6,329 constant 2022 US$ against 6,274 constant 2022 US$ in Benin, a difference of 55 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2019 it was Benin ahead.
Benin ranks 6th and Kazakhstan ranks 5th of 56 countries.
Benin has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Benin | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,550 constant 2022 US$ | 4,830 constant 2022 US$ | 720 constant 2022 US$ | Benin |
| 2020s | 6,274 constant 2022 US$ | 4,806 constant 2022 US$ | 1,468 constant 2022 US$ | Benin |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Benin or Kazakhstan?
- Kazakhstan, at 6,329 constant 2022 US$ against 6,274 constant 2022 US$ in Benin as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Benin and Kazakhstan?
- 55 constant 2022 US$, with Kazakhstan ahead.
- How many years of comparable data are there for Benin and Kazakhstan?
- 5 years are reported by both, from 2019 to 2023.
- How do Benin and Kazakhstan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Benin ranks 6th and Kazakhstan ranks 5th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.